Table 3.
Treatment Outcomes of Patients with Gastric MALT Lymphoma according to the Disease Stage
| Stage IE1 (n=306) | Stage IE2 (n=14) | Stage IIE (n=6) | Stage IIIE (n=2) | Stage IV (n=17) | p-value | |
|---|---|---|---|---|---|---|
| CR after HPE | 255 (83.3) | 10 (71.4) | 4 (66.7) | 2 (100.0) | 13 (76.5) | 0.396 |
| CR* | 267 (87.3) | 12 (85.7) | 5 (83.3) | 2 (100.0) | 15 (88.2) | 0.916 |
| Time to CR, mo | 9.9 (7.2–15.1) | 10.1 (5.7–17.1) | 7.2 (6.2–9.4) | 16.4 (10.6–22.2) | 15.2 (8.1–20.1) | 0.493 |
| Relapse | 28 (10.5) | 1 (8.3) | 0 | 0 | 3 (20.0) | 0.667 |
| Time to relapse, mo | 10.5 (6.2–16.4) | 14.7 | NA | NA | 13.0 (10.0–29.5) | 0.479 |
| CR after relapse | 21/25† (84.0) | 1 (100.0) | NA | NA | 2 (66.7) | NA |
| Treatment failure | 43/303† (14.2) | 2 (14.3) | 1 (16.7) | 0 | 3 (17.6) | 0.930 |
Data are presented as number (%) or median (range).
MALT, mucosa-associated lymphoid tissue; CR, complete remission; HPE, H. pylori eradication therapy; NA, not assessed.
*
Overall CR rate after additional treatment;
†
Two patients have not yet undergone two of the follow-up endoscopies, and one patient was lost to follow-up.